Abstract
This study demonstrates that Anc80L65, a synthetic AAV vector validated to exhibit high expression in the inner ears of neonatal and adult mice, can target both cochlear and vestibular hair cells and spiral ganglion neurons when delivered in utero. These findings support the potential use of Anc80L65 in prenatal gene therapy of hereditary hearing loss.
Original language | English |
---|---|
Pages (from-to) | 493-500 |
Number of pages | 8 |
Journal | Molecular Therapy - Methods and Clinical Development |
Volume | 18 |
DOIs | |
State | Published - 11 Sep 2020 |
Keywords
- AAV2/Anc80L65
- adeno-associated virus
- gene therapy
- hereditary deafness
- in utero microinjection
- inner ears